AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 31, 2019--
Therapeutics, Inc. (NYSE American: AGE), a biotechnology company
focused on developing and commercializing innovative therapeutics for
human aging, announced today that the company will present at Longevity
Leaders, February 4 in London, United Kingdom.
Details of the company’s participation follows.
Monday, February 4, at 200
- Keynote Panel, “The Future of the Science of Aging,” with Michael D.
West, Ph.D., AgeX’s Founder and CEO, and Aubrey de Grey, Ph.D., AgeX’s
VP of New Technology Discovery
Forum, “Building the Biotechs of Aging,” with Dr. West
Presentation on AgeX by Dr. West, as part of a session on leading
companies in the longevity sector
A copy of Dr. West’s presentation deck will be available on the AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing
and commercializing innovative therapeutics for human aging. Its PureStem® and
UniverCyte™manufacturing and immunotolerance technologies are
designed to work together to generate highly defined, universal,
allogeneic, off-the-shelf pluripotent stem cell-derived young cells of
any type for application in a whole host of diseases with a high unmet
medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat
cells) for Type II diabetes. AgeX’s revolutionary longevity platform
named induced Tissue Regeneration (iTR™) aims to unlock cellular
immortality and regenerative capacity to reverse age-related changes
within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical
development. HyStem® is AgeX’s delivery technology to stably
engraft PureStem cell therapies and slowly release iTR molecules in the
body. AgeX is aggressively developing its core product pipeline for use
in the clinic to extend human healthspan, and is seeking opportunities
to form licensing and partnership agreements around its broad IP estate
and proprietary technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com
or connect with the company on Twitter,
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of AgeX Therapeutics, Inc. and
its subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of AgeX’s
Information Statement filed as an exhibit to its Registration Statement
on Form 10 with the Securities and Exchange Commissions (copies of which
may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190131005334/en/
Source: AgeX Therapeutics, Inc.